JPH10221334A - Hemolytic measuring method and microblood collecting tube and reagent kit used therefor - Google Patents

Hemolytic measuring method and microblood collecting tube and reagent kit used therefor

Info

Publication number
JPH10221334A
JPH10221334A JP9038521A JP3852197A JPH10221334A JP H10221334 A JPH10221334 A JP H10221334A JP 9038521 A JP9038521 A JP 9038521A JP 3852197 A JP3852197 A JP 3852197A JP H10221334 A JPH10221334 A JP H10221334A
Authority
JP
Japan
Prior art keywords
tube
hemolytic
blood
blood collection
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9038521A
Other languages
Japanese (ja)
Inventor
Masakatsu Hashimoto
正勝 橋本
Akiko Harada
亜紀子 原田
Yoshio Takahashi
良夫 高橋
Hikari Kitamura
光 北村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHIMA KENKYUSHO KK
Original Assignee
SHIMA KENKYUSHO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHIMA KENKYUSHO KK filed Critical SHIMA KENKYUSHO KK
Priority to JP9038521A priority Critical patent/JPH10221334A/en
Publication of JPH10221334A publication Critical patent/JPH10221334A/en
Pending legal-status Critical Current

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

PROBLEM TO BE SOLVED: To easily measure the main components and trace components of a blood sample by adding a diluted hemolytic sample to an immunological measuring system and measuring antigens or antibodies after dissolving blood cell components by diluting collected blood with a hemolytic diluting solution. SOLUTION: Both ends of a capillary tube 1 having a required length and a uniform inside diameter are opened, with one opening 2 being cut in a circular shape perpendicularly to the axial center of the tube 1, and scale divisions 3 are marked on the surface of the tube 1 on the opening 2 side. Then a flexible tube 5 having an inside diameter which is slightly larger than the outside diameter of the tube 1 is put on the other opening 4 of the tube 1. The tube 1 can be made of glass or a heat-resistant synthetic resin and the flexible tube 5 can be made of a synthetic resin, such as the polyethylene, etc., so that the tube 5 may become flat when the tube 5 is pressed between fingers and can return to its original pipe-like shape when the tube 5 is released from the pressing force. A diluted hemolytic sample is collected by diluting collected blood with a hymolytic diluting solution so as to dissolve blood cell components and added to an immunological measuring system for measuring antigens or antibodies.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【産業上の利用分野】本発明は溶血式測定方法及びそれ
に使用する微量採血管並びに試薬キットにかかるもので
ある。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a hemolytic measuring method, a micro blood collection tube and a reagent kit used for the method.

【0002】[0002]

【従来の技術】従来、医薬品の薬効薬理試験又は副作用
・毒性試験ではマウス、ラット、モルモット等の小動物
を用いて薬物のスクリーニングを行い、次いでウサギ、
ネコ、イヌ等の中型動物に移行し、十分な有効性、安全
性が確認された後、臨床治験を開始するのが通常であ
る。
2. Description of the Related Art Conventionally, in the pharmacological test or the side effect / toxicity test of pharmaceuticals, a drug is screened using small animals such as mice, rats, and guinea pigs, and then rabbits,
Normally, clinical trials are started after transfer to medium-sized animals such as cats and dogs and sufficient efficacy and safety have been confirmed.

【0003】薬物の有効性を確認し判定する方法として
は、目的に応じて種々の検査法が確立されているが、薬
物の副作用或いは毒性を判定する方法としては生殖、発
生毒性試験、癌原性試験、皮膚、眼粘膜、血管等の刺激
性試験、光感作性試験、抗原性試験等があるだけで、動
物の体液の基本構成成分についての測定は、ヘマトクリ
ット値の測定が普及しているのみで、血中の主要構成蛋
白であるアルブミン、IgG、IgA、IgM、補体等
の成分の測定は殆ど行われていないのが実状である。
[0003] As a method for confirming and judging the effectiveness of a drug, various test methods have been established according to the purpose. However, methods for judging the side effect or toxicity of the drug include reproduction, developmental toxicity tests, and carcinogenesis. Hematocrit measurement has become widespread for the measurement of the basic components of animal body fluids, as there are only irritation tests, irritation tests for skin, eye mucosa, blood vessels, etc., photosensitization tests, antigenicity tests, etc. In fact, the measurement of components such as albumin, IgG, IgA, IgM, and complement, which are main constituent proteins in blood, is hardly performed.

【0004】一般的に人体ではアルブミン、IgG、I
gA、IgM、補体蛋白、フィブリノーゲン等が血清蛋
白の約70%を占めているといわれ、それらの体内で果
す役割も非常に大きく、臨床検査においても最も基本的
な測定項目とされている。
[0004] Generally, albumin, IgG, I
It is said that gA, IgM, complement protein, fibrinogen, etc. occupy about 70% of the serum protein, and play a very large role in their body, making them the most basic measurement items in clinical tests.

【0005】従って、薬物の有効性と副作用及び毒性を
確認する動物実験の段階において、これらの血清蛋白の
変動を知ることは重要であり、例えばアルブミンの増減
はその主要産生臓器である肝臓の機能の把握に有効であ
り、又IgG、A、Mの測定は免疫機能に与える影響を
知るうえで有効である。
Therefore, it is important to know the fluctuation of these serum proteins at the stage of animal experiments for confirming the efficacy, side effects and toxicity of the drug. The measurement of IgG, A, and M is effective in knowing the effect on immune function.

【0006】そのため、従来はこれらの血清蛋白の測定
はマウス、ラットの血清を用いて、一元免疫拡散法(S
RID)によって測定していた。
[0006] Therefore, conventionally, these serum proteins have been measured using a one-way immunodiffusion method (S
RID).

【0007】[0007]

【発明が解決しようとする課題】しかしながら、前記血
清成分の測定に必要な充分量の血清をマウス、ラット等
の小動物から採取するには、血液を0.5ml〜1.0
ml採血する必要があるため、動物個体に非常に大きな
負担やダメージを与えることとなり、薬物投与による経
時的或いは経日的な、血液成分の変動を観察することは
困難であった。
However, in order to collect a sufficient amount of serum necessary for the measurement of the serum component from a small animal such as a mouse or rat, the blood must be collected in an amount of 0.5 ml to 1.0 ml.
Since it is necessary to collect ml of blood, an extremely large burden or damage is given to an animal individual, and it has been difficult to observe temporal or daily fluctuations in blood components due to drug administration.

【0008】[0008]

【課題を解決するための手段】本発明は、上述の従来の
課題を解決するためになしたもので、第一の発明は、微
量採血管を用いて採血した血液を溶血性希釈液で希釈し
て血球成分を溶血させ、しかる後該希釈溶血試料を免疫
学的測定系に添加し、抗原又は抗体を測定することを特
徴とする溶血式測定方法である。
Means for Solving the Problems The present invention has been made to solve the above-mentioned conventional problems, and the first invention is to dilute blood collected using a micro blood collection tube with a hemolytic diluent. The hemolysis method is characterized by hemolyzing blood cell components and then adding the diluted hemolyzed sample to an immunological measurement system to measure an antigen or an antibody.

【0009】第二の発明は、両端を開口した内径1mm
φ前後の耐熱性細管の一端側に目盛を設け、且つ他端側
に該細管よりも若干太径で少なくとも検体等の採取・添
加容量以上の内容量を有し且つ手指の押圧力により容易
に変形可能な熱収縮性の可撓性チューブを嵌装すると共
に熱収縮により固定し、該可撓性チューブの他端を一部
又は全部開放し、該可撓性チューブの開放端と前記熱収
縮固定部との間の長さを該開放端側を圧縮により封じ且
つ手指で挟むことにより内容物を放出することができる
長さとしたことを特徴とする微量採血管である。
The second invention has an inner diameter of 1 mm with both ends opened.
A scale is provided on one end side of the heat-resistant thin tube around φ, and the other end side has a slightly larger diameter than the thin tube, has at least the capacity for collecting and adding a sample or the like, and is easily pressed by a finger. A deformable heat-shrinkable flexible tube is fitted and fixed by heat shrink, and the other end of the flexible tube is partially or completely opened, and the open end of the flexible tube and the heat shrink A micro blood collection tube, characterized in that the length between the fixed portion and the fixed portion is such that the open end side can be sealed by compression and the contents can be released by sandwiching with fingers.

【0010】さらに第三の発明は、微量採血管、溶血性
希釈液、抗体感作ラテックス及び希釈液からなることを
特徴とする溶血式試薬キットにかかるものである。
A third aspect of the present invention relates to a hemolytic reagent kit comprising a micro blood collection tube, a hemolytic diluent, an antibody-sensitized latex, and a diluent.

【0011】本発明の測定対象となる動物としては、実
験動物として広く使用されているマウス、ラット、ハム
スター、モルモット、ニワトリ等の小動物があげられる
が、ウサギ、イヌ、ネコ等の中型動物、ヤギ、ヒツジ、
ウシ、ウマ等の大型動物でも実施可能である。
The animals to be measured according to the present invention include small animals such as mice, rats, hamsters, guinea pigs and chickens which are widely used as experimental animals, and medium-sized animals such as rabbits, dogs and cats, and goats. , Sheep,
It can also be carried out on large animals such as cows and horses.

【0012】採血方法としては小動物の場合には眼底静
脈叢穿刺によるのが簡便であるが、尾静脈又は耳静脈の
切断による採血も可能であり、心臓又は頸静脈から採血
した血液を用いることも可能である。
As a blood collection method, in the case of a small animal, it is convenient to puncture the fundus venous plexus, but it is also possible to collect blood by cutting the tail vein or the ear vein, and it is also possible to use blood collected from the heart or jugular vein. It is possible.

【0013】採血の際には内径1mmφ前後の毛細管を
使用すると毛細管現象により自然に血液が吸い上げられ
るので、毛細管に目盛をつけておくことにより容易に必
要量採血することができる。
When blood is collected, if a capillary having an inner diameter of about 1 mmφ is used, blood is naturally drawn up by capillary action. Therefore, it is possible to easily collect a required amount of blood by grading the capillary.

【0014】前記毛細管から採血した血液を吐出するた
めには、直接口にくわえるか又は吐出チューブを接続し
て口にくわえて噴き出してもよく、
In order to discharge blood collected from the capillary tube, the blood may be blown directly into the mouth or by connecting a discharge tube to the mouth.

【図1】に示すように両端を開口した内径1mmφ前後
の耐熱性細管の一端側に目盛を設け、且つ他端側に該細
管よりも若干太径で少なくとも検体等の採取・添加容量
以上の内容量を有し且つ手指の押圧力により容易に変形
可能な熱収縮性の可撓性チューブを嵌装すると共に熱収
縮により固定し、該可撓性チューブの他端を一部又は全
部開放し、該可撓性チューブの開放端と前記熱収縮固定
部との間の長さを該開放端側を圧縮により封じ且つ手指
で挟むことにより内容物を放出することができる長さと
した微量採血管を用いてもよい。
As shown in FIG. 1, a scale is provided at one end of a heat-resistant thin tube having an inner diameter of about 1 mmφ with both ends opened, and has a slightly larger diameter than the thin tube at the other end and has at least the capacity for collecting and adding a sample or the like. A heat-shrinkable flexible tube having an internal capacity and easily deformable by the pressing force of a finger is fitted and fixed by heat shrinkage, and the other end of the flexible tube is partially or entirely opened. A micro blood collection tube having a length between the open end of the flexible tube and the heat-shrinkable fixing portion, the length being such that the open end side can be sealed by compression and the contents can be released by sandwiching with fingers. May be used.

【0015】前記微量採血管を用いると、採血時は毛細
管内が解放されているので血液が毛細管現象により容易
に吸い上げられ、吐出時は可撓性チューブの開放側端部
を折り曲げる等して封じたまま、手指で該可撓性チュー
ブを押圧することにより、細管内の血液が放出される。
With the use of the above-mentioned micro blood collection tube, the blood is easily sucked up by the capillary phenomenon at the time of blood collection because the inside of the capillary is open. At the time of discharge, the open end of the flexible tube is sealed by bending or the like. By pressing the flexible tube with the fingers while keeping it, the blood in the tubule is released.

【0016】前記微量採血管は小動物の眼底静脈叢採血
の際に便利であるが、尾静脈切断法あるいは耳静脈切傷
法により出血させた血液を採取するのも容易である。
The micro blood collection tube is convenient for collecting blood from the fundus venous plexus of a small animal, but it is also easy to collect blood that has been bled by tail vein cutting or ear vein incision.

【0017】心臓穿刺法、頸動脈採血法、断頭採血法、
腹部大動脈切断法、腋窩動脈切断法、股動脈切断法等で
採血した血液を自動ピペット等で一定量採取することも
可能であり、これらの血液に対しても前記微量採血管を
使用することができる。
Heart puncture, carotid blood sampling, decapitation blood sampling,
It is also possible to collect a certain amount of blood collected by an abdominal aorta cutting method, an axillary artery cutting method, a hip artery cutting method, or the like using an automatic pipette or the like. it can.

【0018】また、採血の際に血液の凝固を防止するた
めに、ヘパリン等の抗凝固剤を使用してもよい。
In addition, an anticoagulant such as heparin may be used to prevent coagulation of blood at the time of blood collection.

【0019】以上の操作で採血した血液を溶血し、希釈
する溶血性希釈液としては、水、或いはサポニン等の化
学薬品、蛇毒等の動物性溶血毒、リチン等の植物性溶血
毒、スタフィロリジン等の細菌性溶血毒等のすくなくと
もいずれかを含む生理食塩水、又は血液と等張のリン酸
緩衝液等の緩衝液が使用できる。
Examples of the hemolytic diluent for hemolyzing and diluting the blood collected by the above operation include water, chemicals such as saponin, animal hemolysin such as snake venom, plant hemolysin such as ritin, and staphylo. Physiological saline containing at least any one of bacterial hemolytic toxins such as lysine or a buffer such as a phosphate buffer isotonic with blood can be used.

【0020】溶血毒の濃度は溶血毒の種類により異なる
が、サポニンの場合は0.1〜1.0%程度が適当であ
る。
The concentration of the hemolysin varies depending on the type of the hemolysin, but in the case of saponin, it is suitably about 0.1 to 1.0%.

【0021】測定の対象となる血液蛋白成分としては、
アルブミン、IgG、IgA、IgM、IgD、IgE
等の免疫グロブリン、C3、C4等の補体成分、フェリ
チン、トランスフェリン等の貧血マーカー、ヘモグロビ
ン等の血色素、フィブリノーゲン等の血液凝固因子等、
現在ヒトにおいて測定可能な血液成分と略同様の項目に
適応可能である。
The blood protein components to be measured include:
Albumin, IgG, IgA, IgM, IgD, IgE
Such as immunoglobulins, complement components such as C3 and C4, anemia markers such as ferritin and transferrin, hemoglobin and other hemoglobins, and blood clotting factors such as fibrinogen.
It is applicable to almost the same items as blood components that can be measured in humans at present.

【0022】前記ラテックス免疫比濁法の測定感度は、
使用する抗体のアフィニティーとラテックス粒子の大き
さにより測定感度が異なるが、現在1ng/mlまで測
定可能な技術レベルにあることから、50倍希釈溶血検
体中1ng/mlの濃度、すなわち血液中で50ng/
ml以上の濃度のものは測定可能である。
The measurement sensitivity of the latex immunoturbidimetry is as follows:
The measurement sensitivity varies depending on the affinity of the antibody used and the size of the latex particles. However, since it is at a technical level that can measure up to 1 ng / ml at present, the concentration is 1 ng / ml in a 50-fold diluted hemolyzed sample, that is, 50 ng in blood. /
Those with a concentration of ml or more can be measured.

【0023】希釈溶血した試料を測定する免疫学的測定
系としてはラテックス免疫比濁法が簡便であるが、酵素
免疫測定法、免疫発光分析法、放射免疫測定法等の免疫
定量法も使用することができる。
As an immunological assay system for measuring a diluted hemolyzed sample, a latex immunoturbidimetric assay is convenient, but immunoassays such as an enzyme immunoassay, an immunoluminescence assay, and a radioimmunoassay are also used. be able to.

【0024】前記ラテックス免疫比濁法は、測定しよう
とする抗原又は抗体を含む試料を緩衝液に加え、これに
測定しようとする抗原又は抗体に対応する抗体又は抗原
を感作したラテックス試薬を加えて反応させ、一定時間
後の濁度の変化量を可視又は遠赤外領域における吸光
度、散乱光強度として測定するものである。
In the latex immunoturbidimetry, a sample containing the antigen or antibody to be measured is added to a buffer, and a latex reagent sensitized with an antibody or antigen corresponding to the antigen or antibody to be measured is added to the buffer. And the change in turbidity after a certain time is measured as the absorbance in the visible or far-infrared region and the scattered light intensity.

【0025】測定波長としては500nm〜950nm
を用いるのが、粒子径0.2〜0.5μmのラテックス
粒子を用いて高感度に測定でき、しかも血色素の影響を
受けないので適当である。
The measurement wavelength is 500 nm to 950 nm.
Is suitable because latex particles having a particle diameter of 0.2 to 0.5 μm can be measured with high sensitivity and are not affected by hemoglobin.

【0026】該ラテックス免疫比濁法に近いものとし
て、ラテックス粒子の抗原抗体反応による凝集数を計測
する測定法も本発明に適用可能である。
As a method similar to the latex immunoturbidimetric method, a measuring method for measuring the number of aggregation of latex particles by an antigen-antibody reaction is also applicable to the present invention.

【0027】[0027]

【作用】例えば、マウスを左手で握持して頭部を固定
し、右手に持った微量採血管の目盛側先端をマウスの眼
球の後面部に沿って挿入し、眼底を破るように突いた
後、微量採血管を少し引くと他端に固定した可撓性チュ
ーブが開放状態にあるため、血液が毛細管現象により上
昇してくるので、目盛のところまで上昇したら該微量採
血管を引き抜く。
[Action] For example, the mouse is gripped with the left hand to fix the head, the tip of the micro blood collection tube held in the right hand is inserted along the rear surface of the eyeball of the mouse, and protruded to break the fundus. Thereafter, when the micro blood collection tube is slightly pulled, the flexible tube fixed to the other end is in an open state, and blood rises due to the capillary phenomenon. When the blood reaches the scale, the micro blood collection tube is pulled out.

【0028】次いで、該微量採血管の採血側先端を溶血
性希釈液の入ったサンプルカップ又は試験管の開口部内
に向けた状態で、該微量採血管の後端に固定した可撓性
チューブの開放端部を折り曲げて抑えたまま可撓性チュ
ーブを手指で圧縮すると、採血した血液が前記サンプル
カップの溶血性希釈液内に放出され、該容器を振って攪
拌することにより、速やかに溶血試料が得られる。
Next, with the blood collection side tip of the micro blood collection tube facing the opening of the sample cup or test tube containing the hemolytic diluent, a flexible tube fixed to the rear end of the micro blood collection tube is used. When the flexible tube is compressed by a finger with the open end bent and held, the collected blood is released into the hemolytic diluent of the sample cup, and the sample is quickly shaken by shaking the container and stirring. Is obtained.

【0029】該溶血試料をサンプルカップごと汎用の自
動分析装置のサンプルラックに配置し、自動分析装置の
サンプリングプローブにより溶血試料を20μl採取
し、次いで試薬プローブにより緩衝液を250μl加
え、約5分間、37℃で保温した後、例えば抗マウスI
gM抗体を感作したラテックスを50μl加えると、前
記溶血試料中のIgMとラテックス粒子表面上に感作さ
れた抗IgM抗体とが抗原抗体反応し、IgM量に比例
してラテックス粒子が凝集し、濁度が上昇する。
The hemolyzed sample is placed in a sample rack of a general-purpose automatic analyzer together with the sample cup, and 20 μl of the hemolyzed sample is collected by a sampling probe of the automatic analyzer, and then 250 μl of a buffer is added by a reagent probe, and the sample is added for about 5 minutes. After incubation at 37 ° C., for example, anti-mouse I
When 50 μl of the latex sensitized with the gM antibody was added, the IgM in the hemolyzed sample and the anti-IgM antibody sensitized on the latex particle surface reacted with the antigen-antibody, and the latex particles aggregated in proportion to the IgM amount, Turbidity increases.

【0030】該濁度の上昇を、一定時間(約5分間)後
に吸光度増加量として測定することができ、濃度既知の
IgM標準液を用い、同様に操作して検量線をあらかじ
め作成しておくことにより、希釈検体中のIgM濃度を
定量測定することができ、更に該濃度に希釈倍数を乗算
することによりマウス血液中のIgM濃度を知ることが
できる。
The increase in the turbidity can be measured as an increase in absorbance after a certain period of time (about 5 minutes), and a calibration curve is prepared in advance in the same manner using an IgM standard solution having a known concentration. Thus, the IgM concentration in the diluted sample can be quantitatively measured, and the IgM concentration in the mouse blood can be known by multiplying the concentration by a dilution factor.

【0031】該血液中のIgM濃度をヘマトクリット値
で除算して100を乗算すると血清中のIgM濃度を求
めることができる。
The IgM concentration in serum can be obtained by dividing the IgM concentration in the blood by the hematocrit value and multiplying by 100.

【0032】全血中の血清と血球比率はおおよそ4:3
であるので、4/7を前記血液中のIgM濃度に乗算す
ると血清中のIgM濃度を概算することができる。
The ratio of serum to blood cells in whole blood is approximately 4: 3.
Therefore, the IgM concentration in serum can be estimated by multiplying 4/7 by the IgM concentration in the blood.

【0033】[0033]

【実施例】【Example】

実施例1 Example 1

【図1】は本発明の微量採血管の一例を示したもので、
所要の長さで且つ内径が略均一の細管1の両端を開口
し、該細管1の一方の開口部2を該細管1の軸心と直交
する平面で切断して円形とし、前記細管1の開口部2側
に所要間隔で目盛り3を設け、他の開口部4側に該細管
1の外径よりも若干大きな内径を有する可撓性チューブ
5を嵌装し、該可撓性チューブを前記細管1に固定して
ある。
FIG. 1 shows an example of a micro blood collection tube of the present invention.
Both ends of a thin tube 1 having a required length and a substantially uniform inner diameter are opened, and one opening 2 of the thin tube 1 is cut by a plane perpendicular to the axis of the thin tube 1 to form a circle. Scales 3 are provided at required intervals on the opening 2 side, and a flexible tube 5 having an inner diameter slightly larger than the outer diameter of the thin tube 1 is fitted on the other opening 4 side. It is fixed to the thin tube 1.

【0034】ここで、前記細管1の長さ及び内径は採
取、添加する血液の量に応じて適宜定めることができ、
長さは2cm以上あれば使用可能であるが、操作性、衛
生面を考慮すると5〜10cmが好ましく、内径は1m
mφ前後でよい。又該細管1の素材としてはガラス、或
いは耐熱性の合成樹脂が使用可能である。
Here, the length and inner diameter of the thin tube 1 can be appropriately determined according to the amount of blood to be collected and added.
The length can be used as long as it is 2 cm or more. However, in consideration of operability and hygiene, 5 to 10 cm is preferable, and the inner diameter is 1 m.
It may be around mφ. Glass or heat-resistant synthetic resin can be used as the material of the thin tube 1.

【0035】また可撓性チューブ5の素材としてはポリ
エチレン、ポリプロピレン、ビニール等の合成樹脂を使
用することもできるが、手指で挟んだときに容易につぶ
れ、押圧力を緩めたときに元の円筒状に復元し得るもの
であればよい。
The flexible tube 5 can be made of a synthetic resin such as polyethylene, polypropylene, or vinyl. However, the flexible tube 5 is easily crushed when pinched with fingers, and the original cylinder is released when the pressing force is reduced. Any shape can be used as long as the shape can be restored.

【0036】該可撓性チューブ5の長さは、前記細管1
の容易によるが、該可撓性チューブ5の開放側端部6を
折り曲げて封じた際にも、少なくとも検体等の採取、添
加容量以上の内容量を確保することができる程度とす
る。
The length of the flexible tube 5 is the same as that of the thin tube 1.
However, even when the open-side end 6 of the flexible tube 5 is bent and sealed, at least the collection and addition of a sample or the like can be ensured.

【0037】該可撓性チューブ5を前記細管1に嵌装、
固定する手段としては、可撓性チューブ5の熱収縮を利
用する固定等がある。該可撓性チューブ5の熱収縮を利
用する場合には、細管1に熱収縮性を有する合成樹脂例
えばスミチューブ製の可撓性チューブ5を嵌装した後、
該嵌装部の可撓性チューブ5を部分的に加熱し、熱収縮
させて細管1に固定してもよく、又は細管1の端部を加
熱し、可撓性チューブ5に挿入し、熱収縮させてもよ
い。
The flexible tube 5 is fitted into the thin tube 1,
As means for fixing, there is fixing using heat shrinkage of the flexible tube 5 or the like. When utilizing the heat shrinkage of the flexible tube 5, after fitting the flexible tube 5 made of a heat-shrinkable synthetic resin such as Sumitube into the thin tube 1,
The flexible tube 5 of the fitting portion may be partially heated and heat-shrinked to be fixed to the thin tube 1, or the end of the thin tube 1 may be heated and inserted into the flexible tube 5, It may be contracted.

【0038】実施例2 サポニン0.5gを100mlの生理食塩水に溶解し溶
血性希釈液を調製した。
Example 2 0.5 g of saponin was dissolved in 100 ml of physiological saline to prepare a hemolytic diluent.

【0039】実施例3 市販の粒子径0.2μmのポリスチレンラテックス粒子
に、ヤギ抗ラットIgG抗体を常法により物理吸着させ
て感作する。0.1%BSAを含む0.2Mグリシン−
NaCl緩衝液(pH7.2)により浮遊して感作ラテ
ックス試薬を得た。
Example 3 A commercially available polystyrene latex particle having a particle size of 0.2 μm is sensitized by physically adsorbing a goat anti-rat IgG antibody by a conventional method. 0.2M glycine containing 0.1% BSA
The sensitized latex reagent was obtained by floating with a NaCl buffer (pH 7.2).

【0040】BSA0.1gを0.1Mグリシン−Na
Cl緩衝液に溶解して反応用緩衝液を調製した。
0.1 g of BSA was added to 0.1 M glycine-Na
A reaction buffer was prepared by dissolving in a Cl buffer.

【0041】実施例4 ウィスター系ラットの手足をひもにより固定台に固定
し、尾静脈を尾のつけ根から約2cmのところでメスに
より切断し、にじみ出る血液を実施例1で得た微量採血
管で7μl採取した。
Example 4 The limbs of Wistar rats were fixed to a fixed base with a cord, and the tail vein was cut with a scalpel at a distance of about 2 cm from the base of the tail. The oozing blood was collected in 7 μl using the micro blood collection tube obtained in Example 1. Collected.

【0042】次いで、該微量採血管の採血側先端を実施
例2で調製した溶血性希釈液200μlを入れたサンプ
ルカップに向けて、血液をサンプルカップ中に放出し
た。該放出は微量採血管の可撓性チューブの開放端を折
り曲げて封じたまま手指で該可撓性チューブを押圧する
ことにより行った。
Next, the blood collection side tip of the micro blood collection tube was directed toward a sample cup containing 200 μl of the hemolytic diluent prepared in Example 2, and the blood was released into the sample cup. The release was performed by pressing the flexible tube with fingers while bending and sealing the open end of the flexible tube of the micro blood collection tube.

【0043】前記サンプルカップを振って攪拌、溶血さ
せる。該溶血サンプル3μlに実施例3の緩衝液300
μlを加え、次いで抗ラットIgG抗体感作ラテックス
試薬を50μl加え、反応開始後1分と5分の0.57
μmにおける吸光度(OD×10000)を測定し、吸
光度差を求めたところ1849であった。
The sample cup is shaken to stir and hemolyze. The buffer 300 of Example 3 was added to 3 μl of the hemolyzed sample.
Then, 50 μl of anti-rat IgG antibody-sensitized latex reagent was added, and 0.57 min at 1 minute and 5 min after the start of the reaction.
The absorbance at μm (OD × 10000) was measured and the difference in absorbance was determined to be 1849.

【0044】ラットIgG標準液を用いて前記と同様に
操作しIgG濃度と吸光度差の関係を求めて
Using a rat IgG standard solution, the same operation as above was performed to determine the relationship between the IgG concentration and the absorbance difference.

【図2】に示す標準曲線を作成した。The standard curve shown in FIG. 2 was created.

【0045】該標準曲線を用いて前記ラットの溶血検体
の吸光度差からIgG濃度を求めたところ28.67m
g/dlであり、希釈倍数31倍を乗算すると全血中の
IgG濃度は888.8mg/dlとなり、更にヘマト
クリット値が43%であったので血清中のIgG濃度は
1555.4mg/dlであることが判明した。
Using the standard curve, the IgG concentration was determined from the absorbance difference of the hemolyzed sample of the rat.
g / dl, multiplied by a dilution factor of 31 times, the IgG concentration in whole blood was 888.8 mg / dl, and since the hematocrit value was 43%, the IgG concentration in serum was 1555.4 mg / dl. It has been found.

【0046】実施例5 ウサギ抗モルモットアルブミン抗体を前記実施例3と同
様にラテックス粒子に感作して感作ラテックス試薬を得
た。
Example 5 A rabbit anti-guinea pig albumin antibody was sensitized to latex particles in the same manner as in Example 3 to obtain a sensitized latex reagent.

【0047】モルモット5匹を固定台に夫々固定し、微
量採血管を用いて眼底静脈叢から血清を14μl順次採
取し、それぞれ400μlの溶血性希釈液に実施例4と
同様に添加して測定した。標準曲線は
Five guinea pigs were fixed on a fixed base, respectively, and 14 μl of serum was sequentially collected from the fundus venous plexus using a micro blood collection tube, and added to 400 μl of the hemolytic diluent in the same manner as in Example 4 for measurement. . The standard curve is

【図3】に示す通りであり、溶血検体中のアルブミン濃
度及び推定ヘマトクリット値45%で補正して血清中の
アルブミン濃度を計算した結果は
FIG. 3 shows the results of calculating the albumin concentration in the serum corrected by the albumin concentration in the hemolyzed sample and the estimated hematocrit value of 45%.

【表1】 の通りであった。[Table 1] It was as follows.

【0048】実施例6 ヒツジ抗ラットIgE抗体を市販の0.5μmのポリス
チレンラテックス粒子に実施例3と同様に感作して感作
ラテックス試薬を得た。
Example 6 A sensitized latex reagent was obtained by sensitizing a sheep anti-rat IgE antibody to commercially available 0.5 μm polystyrene latex particles in the same manner as in Example 3.

【0049】ラットを左手で把持して頭部を固定し、右
手に持った微量採血管の目盛側先端をラットの眼球の後
面部に沿って挿入し、眼底を破るように突いた後、微量
採血管を少し引くと他端に固定した可撓性チューブが開
放状態にあるため、毛細管現象により血液が毛細管内を
上昇してくるので、7μlの目盛のところまで上昇した
ら微量採血管を引き抜く。
The rat was grasped with the left hand to fix the head, the tip of the micro blood collection tube held in the right hand was inserted along the rear surface of the rat's eyeball, and after protruding to break the fundus, When the blood collection tube is pulled slightly, the flexible tube fixed to the other end is in an open state, and blood rises in the capillary tube due to capillary action. When the blood rises to the 7 μl scale, the micro blood collection tube is withdrawn.

【0050】その後、実施例4と同様に操作し、得られ
た溶血試料20μlに実施例3の緩衝液250μlを加
え、次いで抗ラットIgE抗体感作ラテックス試薬を5
0μl加え、反応開始後1分と5分の0.7μmにおけ
る吸光度を測定し、吸光度差を求めたところ
Thereafter, the same operation as in Example 4 was carried out, 250 μl of the buffer solution of Example 3 was added to 20 μl of the obtained hemolyzed sample, and then 5 μl of the anti-rat IgE antibody-sensitized latex reagent was added.
0 μl was added, and the absorbance at 0.7 μm at 1 minute and 5 minutes after the start of the reaction was measured to determine the difference in absorbance.

【表2】 の通りであった。[Table 2] It was as follows.

【0051】ラットIgE標準液を用いて前記と同様に
操作し、IgE濃度と吸光度差の関係を求めて
Using a rat IgE standard solution, the same operation as above was performed to determine the relationship between the IgE concentration and the absorbance difference.

【図4】に示す標準曲線を作成した。The standard curve shown in FIG. 4 was created.

【0052】該標準曲線を用いて前記ラットの溶血検体
のIgE濃度を求め、次に希釈倍数31倍を乗算した全
血中のIgE濃度、及び推定ヘマトクリット値を用いて
血清中のIgE濃度を求めたところ
Using the standard curve, the IgE concentration of the hemolyzed sample of the rat was determined, and then the IgE concentration in whole blood multiplied by a dilution factor of 31 and the IgE concentration in serum using the estimated hematocrit value were determined. Where

【表2】の通りであった。Table 2 shows the results.

【0053】[0053]

【発明の効果】以上述べたように本発明によれば下記の
種々の優れた効果が得られる。
As described above, according to the present invention, the following various excellent effects can be obtained.

【0054】1.本発明の方法によれば、微量採血管を
用いて採血した血液を溶血性希釈液で希釈溶血し、免疫
学的測定法で測定するので、血液中の主要構成成分及び
微量成分を容易に定量測定することができる。
1. According to the method of the present invention, blood collected using a micro blood collection tube is diluted and hemolyzed with a hemolytic diluent, and measured by an immunoassay, so that the main constituent components and the micro components in the blood can be easily quantified. Can be measured.

【0055】2.微量採血管を用いることにより、微量
の血液を採取するだけでよいので、採血が容易であり動
物個体に与える負荷も最小限となり、繰り返し採血が可
能となり、薬物等の作用又は副作用・毒性等を長期間に
わたって測定することができる。
2. By using a small blood collection tube, it is only necessary to collect a small amount of blood, so blood collection is easy and the load on individual animals is minimized, blood collection can be repeated, and the action or side effects / toxicity etc. of drugs etc. can be reduced. It can be measured over a long period of time.

【0056】3.溶血測定するので従来必要としていた
血球成分と血漿又は血清とを分ける遠心分離操作が不要
となり、操作が著しく簡便となる。又分離操作が不要な
ので採血量も少なくて済む。
3. Since the hemolysis measurement is performed, the centrifugal separation operation for separating the blood cell component from the plasma or serum, which has been conventionally required, becomes unnecessary, and the operation becomes extremely simple. Also, since no separation operation is required, the amount of blood collected can be reduced.

【0057】4.以上の効果により、医薬品等の薬効又
は副作用域は毒性等を動物実験の段階で人体におけると
同様のレベルで詳細に且つ長期にわたって評価・判定す
ることができるため、安全で優れた薬効を持つ医薬品の
開発が経済的且つ確実に行える。
4. Because of the above effects, the drug efficacy or side effect range of drugs and the like can be evaluated and determined over a long period of time at the animal test stage at the same level as in the human body, and therefore, drugs with safe and excellent drug efficacy Can be developed economically and reliably.

【図面の簡単な説明】[Brief description of the drawings]

【図1】本発明の一実施例を示した説明図である。FIG. 1 is an explanatory diagram showing one embodiment of the present invention.

【図2】本発明の効果を示した説明図である。FIG. 2 is an explanatory diagram showing an effect of the present invention.

【図3】本発明の効果を示した説明図である。FIG. 3 is an explanatory diagram showing an effect of the present invention.

【図4】本発明の効果を示した説明図である。FIG. 4 is an explanatory diagram showing an effect of the present invention.

Claims (12)

【特許請求の範囲】[Claims] 【請求項1】 微量採血管を用いて採血した血液を、溶
血性希釈液で希釈して血球成分を溶血させ、しかる後該
希釈溶血試料を免疫学的測定系に添加し、抗原又は抗体
を測定することを特徴とする溶血式測定方法。
1. A blood sample collected using a micro blood collection tube is diluted with a hemolytic diluent to lyse blood cell components, and thereafter, the diluted hemolyzed sample is added to an immunological assay system, and an antigen or antibody is added. A hemolytic measuring method characterized by measuring.
【請求項2】 小動物から微量採血管を用いて採血する
請求項1記載の溶血式測定方法。
2. The method according to claim 1, wherein blood is collected from a small animal using a micro blood collection tube.
【請求項3】 小動物がマウス、ラット、ハムスター、
モルモット、ニワトリのいずれかである請求項2記載の
溶血式測定方法。
3. The small animal is a mouse, rat, hamster,
The method according to claim 2, wherein the method is a guinea pig or a chicken.
【請求項4】 採血を眼底静脈叢穿刺、尾静脈採血のい
ずれかにより行う請求項1記載の溶血式測定方法。
4. The method according to claim 1, wherein blood collection is performed by puncture of the fundus venous plexus or blood collection of the tail vein.
【請求項5】 溶血性希釈液が水、溶血毒を含有する溶
血剤のいずれかである請求項1記載の溶血式測定方法。
5. The method according to claim 1, wherein the hemolytic diluent is water or a hemolytic agent containing a hemolytic toxin.
【請求項6】 溶血毒がサポニンである請求項5記載の
溶血式測定方法。
6. The method according to claim 5, wherein the hemolysin is saponin.
【請求項7】 免疫学的測定系が、ラテックス免疫凝集
比濁法、免疫比濁法、酵素免疫測定法、免疫発光分析法
のいずれかである請求項1記載の溶血式測定方法。
7. The method according to claim 1, wherein the immunological measurement system is any one of latex immunoagglutination turbidimetry, immunoturbidimetry, enzyme immunoassay, and immunoluminescence analysis.
【請求項8】 測定する抗原がアルブミン、IgG、I
gA、IgM、C3、C4、フィブリノーゲン、トラン
スフェリン、フェリチン、ヘモグロビン、β2−マイク
ログロブリン、CRP、IgEのいずれかである請求項
1記載の溶血式測定方法。
8. The antigen to be measured is albumin, IgG, I
The method according to claim 1, wherein the method is any one of gA, IgM, C3, C4, fibrinogen, transferrin, ferritin, hemoglobin, β2-microglobulin, CRP, and IgE.
【請求項9】 両端を開口した内径1mmφ前後の耐熱
性細管の一端側に目盛を設け、且つ他端側に該細管より
も若干太径で少なくとも検体等の採取・添加容量以上の
内容量を有し且つ手指の押圧力により容易に変形可能な
熱収縮性の可撓性チューブを嵌装すると共に熱収縮によ
り固定し、該可撓性チューブの他端を一部又は全部開放
し、該可撓性チューブの開放端と前記熱収縮固定部との
間の長さを該開放端側を圧縮により封じ且つ手指で挟む
ことにより内容物を放出することができる長さとしたこ
とを特徴とする微量採血管。
9. A scale is provided at one end of a heat-resistant thin tube having an inner diameter of about 1 mmφ with both ends opened, and the other end has a slightly larger diameter than the thin tube and has an inner capacity larger than at least the collection / addition capacity of a sample or the like. A heat-shrinkable flexible tube, which is capable of being deformed easily by the pressing force of a finger, is fitted and fixed by heat shrinkage, and the other end of the flexible tube is partially or entirely opened. The length between the open end of the flexible tube and the heat-shrinkable fixing portion is set to a length that allows the content to be released by sealing the open end side by compression and sandwiching it with fingers. Blood collection tube.
【請求項10】 微量採血管、溶血性希釈液、抗体感作
ラテックス及び希釈液からなることを特徴とする溶血式
試薬キット。
10. A hemolytic reagent kit comprising a micro blood collection tube, a hemolytic diluent, an antibody-sensitized latex, and a diluent.
【請求項11】 7μl又は14μl採取用の微量採血
管、溶血性希釈液200μl又は400μl入サンプル
チップ、抗体感作ラテックス試薬、及び反応用緩衝液か
らなる請求項10記載の溶血式試薬キット。
11. The hemolytic reagent kit according to claim 10, comprising a micro blood collection tube for collecting 7 μl or 14 μl, a sample chip containing 200 μl or 400 μl of a hemolytic diluent, an antibody-sensitized latex reagent, and a reaction buffer.
【請求項12】 溶血性希釈液がサポニン溶液である請
求項10記載の溶血式試薬キット。
12. The hemolytic reagent kit according to claim 10, wherein the hemolytic diluent is a saponin solution.
JP9038521A 1997-02-07 1997-02-07 Hemolytic measuring method and microblood collecting tube and reagent kit used therefor Pending JPH10221334A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP9038521A JPH10221334A (en) 1997-02-07 1997-02-07 Hemolytic measuring method and microblood collecting tube and reagent kit used therefor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9038521A JPH10221334A (en) 1997-02-07 1997-02-07 Hemolytic measuring method and microblood collecting tube and reagent kit used therefor

Publications (1)

Publication Number Publication Date
JPH10221334A true JPH10221334A (en) 1998-08-21

Family

ID=12527586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9038521A Pending JPH10221334A (en) 1997-02-07 1997-02-07 Hemolytic measuring method and microblood collecting tube and reagent kit used therefor

Country Status (1)

Country Link
JP (1) JPH10221334A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005218677A (en) * 2004-02-06 2005-08-18 Enomoto Co Ltd Quantitative blood sampling kit
JP2007209478A (en) * 2006-02-08 2007-08-23 Morinaga & Co Ltd Blood-collecting vessel for small animal, and blood collecting apparatus for small animal using the same
JP2008011880A (en) * 2006-06-30 2008-01-24 Sakae:Kk Liquid collector
JP2008512164A (en) * 2004-09-13 2008-04-24 マイクロサンプル リミテッド Method and apparatus for collecting and analyzing fluid
WO2011100595A3 (en) * 2010-02-12 2011-12-29 Northwestern University Methods and devices for sample collection, treatment and dispensing
WO2017006963A1 (en) * 2015-07-06 2017-01-12 富士フイルム株式会社 Blood test kit and analysis method using same
JP2017015710A (en) * 2015-07-06 2017-01-19 富士フイルム株式会社 Blood test kit and analysis method using the same
JP6104440B1 (en) * 2016-08-17 2017-03-29 株式会社エム・ビー・エス Blood collection device including blood collection device and blood container
JP2021515899A (en) * 2018-03-02 2021-06-24 テレフレックス メディカル インコーポレイテッド Infection detection system and method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5967935A (en) * 1982-10-08 1984-04-17 テルモ株式会社 Blood sampling instrument
JPS60244861A (en) * 1984-05-19 1985-12-04 Masakatsu Hashimoto Hemolysis type measuring method and reagent kit used therein
JPH05304983A (en) * 1992-04-27 1993-11-19 Nissin Food Prod Co Ltd Substrate for determining protease-inhibiting protein in human urine and determination method
JPH06141852A (en) * 1992-10-30 1994-05-24 Nichirei Corp Antibody and hybridoma producing the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5967935A (en) * 1982-10-08 1984-04-17 テルモ株式会社 Blood sampling instrument
JPS60244861A (en) * 1984-05-19 1985-12-04 Masakatsu Hashimoto Hemolysis type measuring method and reagent kit used therein
JPH05304983A (en) * 1992-04-27 1993-11-19 Nissin Food Prod Co Ltd Substrate for determining protease-inhibiting protein in human urine and determination method
JPH06141852A (en) * 1992-10-30 1994-05-24 Nichirei Corp Antibody and hybridoma producing the same

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005218677A (en) * 2004-02-06 2005-08-18 Enomoto Co Ltd Quantitative blood sampling kit
JP2008512164A (en) * 2004-09-13 2008-04-24 マイクロサンプル リミテッド Method and apparatus for collecting and analyzing fluid
JP2007209478A (en) * 2006-02-08 2007-08-23 Morinaga & Co Ltd Blood-collecting vessel for small animal, and blood collecting apparatus for small animal using the same
JP2008011880A (en) * 2006-06-30 2008-01-24 Sakae:Kk Liquid collector
WO2011100595A3 (en) * 2010-02-12 2011-12-29 Northwestern University Methods and devices for sample collection, treatment and dispensing
US8841127B2 (en) 2010-02-12 2014-09-23 Northwestern University Methods and devices for sample collection, treatment and dispensing
WO2017006963A1 (en) * 2015-07-06 2017-01-12 富士フイルム株式会社 Blood test kit and analysis method using same
JP2017015710A (en) * 2015-07-06 2017-01-19 富士フイルム株式会社 Blood test kit and analysis method using the same
US10697870B2 (en) 2015-07-06 2020-06-30 Fujifilm Corporation Blood test kit and analyzing method using the same
JP6104440B1 (en) * 2016-08-17 2017-03-29 株式会社エム・ビー・エス Blood collection device including blood collection device and blood container
WO2018034032A1 (en) * 2016-08-17 2018-02-22 株式会社エム・ビー・エス Blood sampler and blood sampling tool comprising blood container
JP2018027190A (en) * 2016-08-17 2018-02-22 株式会社エム・ビー・エス Blood collection tool including blood collector and blood storage container
JP2021515899A (en) * 2018-03-02 2021-06-24 テレフレックス メディカル インコーポレイテッド Infection detection system and method

Similar Documents

Publication Publication Date Title
Von dem Borne et al. Autoimmune thrombocytopenia: detection of platelet autoantibodies with the suspension immunofluorescence test
STATS et al. Cold hemagglutination—an interpretive review
Blais et al. Canine Dal blood type: a red cell antigen lacking in some Dalmatians
Sobotka et al. Allergy to insect stings: IV. Diagnosis by radioallergosorbent test (RAST)
US7410807B2 (en) Pregnancy and sex identification test based on saliva or other bodily fluids
DK174032B1 (en) Kit as well as immunometric dosing method that can be applied to whole cells
US4233286A (en) Low affinity IGM-latex particles and assay therewith for immune complexes
JPH10221334A (en) Hemolytic measuring method and microblood collecting tube and reagent kit used therefor
EP0070278B1 (en) A method of diagnosis
US4141965A (en) Assay of immune complexes
US4454226A (en) Enzymatic immunoassay
EP0265851B1 (en) Method for the determination of anti-HIV, means therefor and their use in this method
JP2642721B2 (en) Method for detecting antibodies to human immunodeficiency virus
Pondman et al. The specificity of the complement antiglobulin test
Koller et al. Lupus erythematosus cell preparation-antinuclear factor incongruity: a review of diagnostic tests for systemic lupus erythematosus
EP1386160A2 (en) Method for detecting blood cell antigens and the antibodies in response to the same
Fabijanska‐Mitek et al. The value of gel test and ELAT in autoimmune haemolytic anaemia
JP2006153523A (en) Immunochromatograph method using noninvasive specimen
JPS604423B2 (en) Method for quantifying peptide hormones
US5637472A (en) Hydrazine derivatized cells
JPH0325366A (en) Method for measuring specific antibody
Goodwin et al. RAST using crude and purified anti‐IgE
EP0132537A1 (en) Immunoassay
JPS60244861A (en) Hemolysis type measuring method and reagent kit used therein
JPH05346428A (en) Kit for rapidly counting granulocyte and method using the kit

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20050803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20051221